JP2015529236A - ヘテロ二量体免疫グロブリンの精製 - Google Patents

ヘテロ二量体免疫グロブリンの精製 Download PDF

Info

Publication number
JP2015529236A
JP2015529236A JP2015532465A JP2015532465A JP2015529236A JP 2015529236 A JP2015529236 A JP 2015529236A JP 2015532465 A JP2015532465 A JP 2015532465A JP 2015532465 A JP2015532465 A JP 2015532465A JP 2015529236 A JP2015529236 A JP 2015529236A
Authority
JP
Japan
Prior art keywords
immunoglobulin
region
fragment
amino acid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015532465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015529236A5 (US07714131-20100511-C00024.png
Inventor
ブレイン，スタニスラス
コンペル，ファブリツィオ
オリエル，ロメイン
ワスマン，ポール
Original Assignee
グレンマーク ファーマシューティカルズ， エセ．アー．
グレンマーク ファーマシューティカルズ， エセ．アー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グレンマーク ファーマシューティカルズ， エセ．アー．, グレンマーク ファーマシューティカルズ， エセ．アー． filed Critical グレンマーク ファーマシューティカルズ， エセ．アー．
Publication of JP2015529236A publication Critical patent/JP2015529236A/ja
Publication of JP2015529236A5 publication Critical patent/JP2015529236A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015532465A 2012-09-25 2013-09-25 ヘテロ二量体免疫グロブリンの精製 Pending JP2015529236A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705278P 2012-09-25 2012-09-25
US61/705,278 2012-09-25
PCT/EP2013/069989 WO2014049003A1 (en) 2012-09-25 2013-09-25 Purification of hetero-dimeric immunoglobulins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2018020450A Division JP2018104444A (ja) 2012-09-25 2018-02-07 ヘテロ二量体免疫グロブリンの精製
JP2018224809A Division JP6856610B2 (ja) 2012-09-25 2018-11-30 ヘテロ二量体免疫グロブリンの精製

Publications (2)

Publication Number Publication Date
JP2015529236A true JP2015529236A (ja) 2015-10-05
JP2015529236A5 JP2015529236A5 (US07714131-20100511-C00024.png) 2016-11-10

Family

ID=49237223

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015532465A Pending JP2015529236A (ja) 2012-09-25 2013-09-25 ヘテロ二量体免疫グロブリンの精製
JP2018020450A Pending JP2018104444A (ja) 2012-09-25 2018-02-07 ヘテロ二量体免疫グロブリンの精製
JP2018224809A Active JP6856610B2 (ja) 2012-09-25 2018-11-30 ヘテロ二量体免疫グロブリンの精製
JP2020036853A Ceased JP2020105203A (ja) 2012-09-25 2020-03-04 ヘテロ二量体免疫グロブリンの精製
JP2022092045A Pending JP2022116326A (ja) 2012-09-25 2022-06-07 ヘテロ二量体免疫グロブリンの精製

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018020450A Pending JP2018104444A (ja) 2012-09-25 2018-02-07 ヘテロ二量体免疫グロブリンの精製
JP2018224809A Active JP6856610B2 (ja) 2012-09-25 2018-11-30 ヘテロ二量体免疫グロブリンの精製
JP2020036853A Ceased JP2020105203A (ja) 2012-09-25 2020-03-04 ヘテロ二量体免疫グロブリンの精製
JP2022092045A Pending JP2022116326A (ja) 2012-09-25 2022-06-07 ヘテロ二量体免疫グロブリンの精製

Country Status (11)

Country Link
US (2) US20150239991A1 (US07714131-20100511-C00024.png)
EP (2) EP3401337A1 (US07714131-20100511-C00024.png)
JP (5) JP2015529236A (US07714131-20100511-C00024.png)
KR (1) KR20150076172A (US07714131-20100511-C00024.png)
CN (1) CN104968685A (US07714131-20100511-C00024.png)
AU (2) AU2013322710A1 (US07714131-20100511-C00024.png)
CA (2) CA3061557A1 (US07714131-20100511-C00024.png)
HK (1) HK1215950A1 (US07714131-20100511-C00024.png)
IL (2) IL237872B (US07714131-20100511-C00024.png)
IN (1) IN2015MN00139A (US07714131-20100511-C00024.png)
WO (1) WO2014049003A1 (US07714131-20100511-C00024.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020105203A (ja) * 2012-09-25 2020-07-09 イクノス サイエンシズ エスエー ヘテロ二量体免疫グロブリンの精製

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
EP2417156B1 (en) 2009-04-07 2015-02-11 Roche Glycart AG Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
RU2573915C2 (ru) 2009-09-16 2016-01-27 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применение
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
EP2681239B8 (en) 2011-02-28 2015-09-09 F. Hoffmann-La Roche AG Antigen binding proteins
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
UA118029C2 (uk) 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
EP3041865A2 (en) * 2013-09-03 2016-07-13 NovImmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
EP3055329B1 (en) 2013-10-11 2018-06-13 F. Hoffmann-La Roche AG Multispecific domain exchanged common variable light chain antibodies
JP2016538275A (ja) * 2013-11-04 2016-12-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造
EP3094648A1 (en) 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Fc-region variants with improved protein a-binding
CN111410691B (zh) 2014-03-28 2024-02-13 Xencor公司 结合至cd38和cd3的双特异性抗体
AR101262A1 (es) * 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
EP3174897B1 (en) * 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
WO2016086196A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
CN117069855A (zh) 2015-10-25 2023-11-17 赛诺菲 用于预防或治疗hiv感染的三特异性和/或三价结合蛋白
GB201602156D0 (en) * 2016-02-05 2016-03-23 Jones Philip C And Boku University Of Natural Resources And Life Sciences Heterodimers and purification thereof
KR20180134378A (ko) 2016-04-13 2018-12-18 사노피 3특이성 및/또는 3가 결합 단백질
KR20240036142A (ko) 2016-04-13 2024-03-19 사노피 3특이성 및/또는 3가 결합 단백질
EP3889175A1 (en) * 2016-05-02 2021-10-06 F. Hoffmann-La Roche AG The contorsbody - a single chain target binder
EP3504234A4 (en) * 2016-09-29 2020-12-02 Beijing Hanmi Pharmaceutical Co., Ltd. HETERODIMER IMMUNOGLOBULIN CONSTRUCTS AND MANUFACTURING PROCESSES
BR112019010051A2 (pt) 2016-11-18 2019-09-03 Beijing Hanmi Pharmaceutical Co Ltd anticorpo biespecífico heterodimérico, polinucleotídeo isolado, vetor de expressão recombinante, célula hospedeira, composição, método de produzir o anticorpo biespecífico heterodimérico, uso do anticorpo bieífico heterodimérico, e método de prevenir e/ou tratar uma doença
MX2019012198A (es) 2017-04-11 2020-01-21 Inhibrx Inc Constructos de polipéptidos multiespecíficos que tienen unión limitada a cd3 y métodos de utilización de los mismos.
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
EP3769083A1 (en) 2018-03-21 2021-01-27 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
SG11202009804RA (en) 2018-04-11 2020-11-27 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
FR3080621B1 (fr) * 2018-04-26 2022-12-09 Univ Limoges Nouvelle classe d'immunoglobuline recombinante de type g : igg5, codee par le pseudo-gene gamma humain de chaine lourde
CA3104390A1 (en) 2018-06-22 2019-12-26 Genmab A/S Method for producing a controlled mixture of two or more different antibodies
TW202035451A (zh) 2018-07-24 2020-10-01 美商英伊布里克斯公司 含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
EP3864044A1 (en) 2018-10-11 2021-08-18 Inhibrx, Inc. B7h3 single domain antibodies and therapeutic compositions thereof
CN113166263A (zh) 2018-10-11 2021-07-23 印希比股份有限公司 Dll3单域抗体及其治疗性组合物
WO2020076992A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. 5t4 single domain antibodies and therapeutic compositions thereof
CN113166262A (zh) 2018-10-11 2021-07-23 英伊布里克斯公司 Pd-1单结构域抗体及其治疗组合物
US11739160B2 (en) 2018-12-24 2023-08-29 Sanofi PseudoFab-based multispecific binding proteins
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
CN115003695A (zh) * 2019-12-26 2022-09-02 爱必乐生物公司 一种使用蛋白a亲和层析法纯化生物活性肽的方法
BR112022014667A2 (pt) 2020-01-29 2022-09-20 Inhibrx Inc Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
US12037399B2 (en) 2020-10-07 2024-07-16 Dren Bio, Inc. Anti-Dectin-1 antibodies and methods of use thereof
EP4355783A1 (en) 2021-06-16 2024-04-24 Alector LLC Monovalent anti-mertk antibodies and methods of use thereof
CN117642426A (zh) 2021-06-16 2024-03-01 艾莱克特有限责任公司 双特异性抗MerTK和抗PDL1抗体及其使用方法
WO2023240109A1 (en) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Multispecific molecules for modulating t-cell activity, and uses thereof
WO2024026471A1 (en) 2022-07-29 2024-02-01 Alector Llc Cd98hc antigen-binding domains and uses therefor
WO2024026472A2 (en) 2022-07-29 2024-02-01 Alector Llc Transferrin receptor antigen-binding domains and uses therefor
WO2024050493A2 (en) * 2022-09-02 2024-03-07 Zoetis Services Llc Equine antibody mutants
WO2024102948A1 (en) 2022-11-11 2024-05-16 Celgene Corporation Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543868A (ja) * 2005-06-17 2008-12-04 ワイス Ｆｃ領域含有タンパク質を精製する方法
WO2010151792A1 (en) * 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2011078332A1 (ja) * 2009-12-25 2011-06-30 中外製薬株式会社 ポリペプチド多量体を精製するためのポリペプチドの改変方法
JP2012504403A (ja) * 2008-10-01 2012-02-23 マイクロメット アーゲー 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
JP2012513414A (ja) * 2008-12-23 2012-06-14 ジェネンテック， インコーポレイテッド プロテインａに対する結合が変化した免疫グロブリン変異体

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
KR0149181B1 (ko) 1990-06-29 1998-08-17 데이비드 알, 맥지 형질전환된 미생물에 의한 멜라닌의 제조방법
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE4419399C1 (de) 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
US6322788B1 (en) * 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
US8142780B2 (en) * 1998-08-20 2012-03-27 Strox Biopharmaceuticals, Llc Anti-bacterial antibodies
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
PL2129396T3 (pl) 2007-02-16 2014-02-28 Merrimack Pharmaceuticals Inc Przeciwciała przeciw ERBB3 i ich zastosowania
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
BRPI1005984A2 (pt) 2009-02-23 2016-10-04 Glenmark Pharmaceuticals Sa anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
CN103097417B (zh) * 2010-04-20 2019-04-09 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
BR112013023918A2 (pt) 2011-03-25 2016-12-13 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
US9114516B2 (en) 2011-07-21 2015-08-25 Illinois Tool Works Inc. Portable combustion gas-powered tools with combustion chamber lockout system
HUE044633T2 (hu) * 2011-10-27 2019-11-28 Genmab As Heterodimer fehérjék elõállítása
EP2823422A1 (en) 2012-03-06 2015-01-14 FOSS Analytical AB Method, software and graphical user interface for forming a prediction model for chemometric analysis
DK2825559T3 (da) 2012-03-13 2019-06-03 Novimmune Sa Letisolerbare bispecifikke antistoffer med nativt immunoglobulinformat
IN2015MN00139A (US07714131-20100511-C00024.png) * 2012-09-25 2015-10-16 Glenmark Pharmaceuticals Sa
JP2016538275A (ja) * 2013-11-04 2016-12-08 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543868A (ja) * 2005-06-17 2008-12-04 ワイス Ｆｃ領域含有タンパク質を精製する方法
JP2008543881A (ja) * 2005-06-17 2008-12-04 エラン ファーマ インターナショナル リミテッド 抗Ａβ抗体を精製する方法
JP2012504403A (ja) * 2008-10-01 2012-02-23 マイクロメット アーゲー 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体
JP2012513414A (ja) * 2008-12-23 2012-06-14 ジェネンテック， インコーポレイテッド プロテインａに対する結合が変化した免疫グロブリン変異体
WO2010151792A1 (en) * 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2011078332A1 (ja) * 2009-12-25 2011-06-30 中外製薬株式会社 ポリペプチド多量体を精製するためのポリペプチドの改変方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF IMMUNOLOGICAL METHODS, vol. 201, JPN5015009939, 1997, pages 25 - 34, ISSN: 0003611945 *
STRUCTURE, vol. 3, no. 3, JPN5015009936, 1995, pages 265 - 278, ISSN: 0003611944 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020105203A (ja) * 2012-09-25 2020-07-09 イクノス サイエンシズ エスエー ヘテロ二量体免疫グロブリンの精製

Also Published As

Publication number Publication date
CA2886036A1 (en) 2014-04-03
WO2014049003A1 (en) 2014-04-03
EP2900696A1 (en) 2015-08-05
IL269207A (en) 2019-11-28
EP3401337A1 (en) 2018-11-14
AU2018204314A1 (en) 2018-07-05
AU2013322710A1 (en) 2015-04-16
CN104968685A (zh) 2015-10-07
HK1215950A1 (zh) 2016-09-30
JP6856610B2 (ja) 2021-04-07
IN2015MN00139A (US07714131-20100511-C00024.png) 2015-10-16
JP2018104444A (ja) 2018-07-05
AU2018204314B2 (en) 2020-05-14
KR20150076172A (ko) 2015-07-06
IL237872B (en) 2019-09-26
CA3061557A1 (en) 2014-04-03
IL237872A0 (en) 2015-05-31
JP2020105203A (ja) 2020-07-09
US20200010568A1 (en) 2020-01-09
US20150239991A1 (en) 2015-08-27
AU2013322710A2 (en) 2015-05-07
JP2022116326A (ja) 2022-08-09
IL269207B (en) 2022-02-01
JP2019073512A (ja) 2019-05-16

Similar Documents

Publication Publication Date Title
JP6856610B2 (ja) ヘテロ二量体免疫グロブリンの精製
AU2019257534B2 (en) Production of T cell retargeting hetero-dimeric immunoglobulins
JP7403505B2 (ja) Ｃｄ３／ｃｄ３８ ｔ細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法
OA17758A (en) Production of T cell retargeting heterodimeric immunoglobulins.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160921

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180731